From the Research
Tresiba (insulin degludec) is typically taken once daily, with the flexibility to adjust the injection time as needed, while maintaining its efficacy and safety profile, as demonstrated in a 26-week, randomized, open-label, parallel-group, treat-to-target trial 1. The long-acting nature of Tresiba provides steady insulin coverage for at least 42 hours, which allows for some flexibility in timing if you occasionally need to adjust your injection schedule.
- Your specific dosage will be determined by your healthcare provider based on your individual needs, blood sugar levels, and response to treatment.
- It's essential to follow your prescribed dosage exactly and not make changes without consulting your healthcare provider.
- Tresiba works by slowly releasing insulin into your bloodstream throughout the day and night to help control your blood sugar levels.
- If you miss a dose, take it as soon as you remember, then return to your regular schedule the next day.
- Never double your dose to make up for a missed one, as this could cause dangerously low blood sugar. The efficacy and safety of Tresiba have been evaluated in several studies, including a 26-week, randomized, open-label, parallel-group, treat-to-target trial, which demonstrated that Tresiba can be taken with variable once-daily dosing intervals, similar to insulin glargine, without compromising glycemic control or safety 1. Additionally, a study published in the Journal of the American Medical Association (JAMA) found that Tresiba resulted in a reduced rate of overall symptomatic hypoglycemia compared to insulin glargine U100 in patients with type 2 diabetes 2. Overall, the evidence suggests that Tresiba can be taken once daily, with flexibility in the injection time, while maintaining its efficacy and safety profile, making it a suitable option for patients with type 1 or 2 diabetes who require basal insulin therapy.